Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05170399 · ClinicalTrials.gov registry record · Phase 4
Vaccine Responses in Patients With B Cell Malignancies
A Phase 4 study of Lymphoma, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT05170399 is a Phase 4 study of Lymphoma that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 500 participants, roughly in line with the 482-participant average among 299 other Lymphoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT05170399, a Phase 4 study of Lymphoma, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers want to learn more about vaccine responses in people with certain types of blood cancers. The findings may help develop better vaccine strategies for people with these cancers. Objective: To learn how well vaccines work in people who have certain types of blood cancers. Eligibility: Adults aged 18 years or older who have chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, or certain non-Hodgkin lymphomas. Design: Participants will get one or more vaccines for illnesses such as COVID-19, hepatitis B, and shingles. They can choose which vaccines they receive. They will give a blood sample before they get each vaccine. Some vaccines require a second dose 3-6 weeks later. Participants may give an optional blood sample with the second vaccine dose. About 4 weeks after they finish each vaccine series, they will give another blood sample. They will have 2-3 study visits per vaccine. Participants may receive a booster dose for some vaccines. The booster dose is optional. They will give another blood sample with the booster dose. Participants will have pregnancy tests, if needed. Participants with CLL who receive BTKis may be asked to pause treatment for up to 7 weeks. Participants may give follow-up blood samples up to 2 times a year for 5 years. These blood samples are optional. Participation will last for up to 5 years after each vaccine series is received.
Conditions Studied
Interventions
- BIOLOGICAL Shingrix
- BIOLOGICAL Fluzone
- BIOLOGICAL Flucelvax
- BIOLOGICAL Afluria
- BIOLOGICAL PREVNAR 13
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-09-14 |
| Est. Completion | 2026-08-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05170399
The ClinicalTrials.gov registry entry for NCT05170399 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 482-participant average among 299 other Lymphoma trials with a reported enrollment target. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Shingrix is the first listed.
NCT05170399 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05170399 about?
NCT05170399 is a clinical study titled "Vaccine Responses in Patients With B Cell Malignancies". Background: People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers ...
What is the current status of trial NCT05170399?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2022-09-14. Estimated completion is 2026-08-16.
What conditions does trial NCT05170399 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT05170399?
The interventions under investigation include: Shingrix (BIOLOGICAL), Fluzone (BIOLOGICAL), Flucelvax (BIOLOGICAL), Afluria (BIOLOGICAL), PREVNAR 13 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05170399?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05170399 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
ACTIVE NOT RECRUITING · Phase 4
-
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
COMPLETED · Phase 4
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.